Negara: Irlandia
Bahasa: Inggris
Sumber: HPRA (Health Products Regulatory Authority)
Amoxicillin trihydrate; Potassium clavulanate
LIVISTO Int'l, S.L.
QJ01CR02
Amoxicillin trihydrate; Potassium clavulanate
500/125 mg/tablet
Tablet
POM: Prescription Only Medicine as defined in relevant national legislation
amoxicillin and enzyme inhibitor
Authorised
2021-05-28
1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYLANIC 500 mg + 125 mg tablets for dogs. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCES: Amoxicillin (as amoxicillin trihydrate) 500 mg Clavulanic acid (as potassium clavulanate) 125 mg EXCIPIENTS: For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets. White to slightly yellow, round and convex tablet with a cross-shaped break line on one side. The tablets can be divided into 2 or 4 equal parts. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For treatment of infections caused by bacteria susceptible to amoxicillin and clavulanic acid including: skin disease (including deep and superficial pyodermas); soft tissue infections (abscesses and anal sacculitis); dental infections (e.g. gingivitis); urinary tract infections; respiratory disease (involving upper and lower respiratory tract); enteritis. 4.3 CONTRAINDICATIONS Do not use in rabbits, guinea pigs, hamsters, gerbils or chinchillas. Do not use in known cases of hypersensitivity to the active substances, to other antimicrobials of the β-lactam group or to any of the excipients. Do not use in animals with serious dysfunction of the kidneys accompanied by anuria and oliguria. Do not use in ruminants and horses. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals Official, national and regional antimicrobial policies should be taken into account when the product is used. The association amoxicillin/clavulanic acid should be reserved for the treatment of clinical conditions which have responded poorly to other classes of antimicrobials or narrow spectrum penicillins. Whenever possible, the association amoxicillin/clavulanic acid should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to amoxicillin/clavulanic acid and may Baca dokumen lengkapnya